COMBINED TREATMENT FOR CHRONIC MIGRAINE: BOTULINUM TOXIN TYPE A AND VENLAFAXINE

Download full text PDF
Issue: 
10
Year: 
2017

K. Tatarinova (1, 2); A. Artemenko (1), MD 1-I.M. Sechenov First Moscow State Medical University (Sechenov University) 2-A.S. Lukashevsky Kamchatka Territorial Hospital, Petropavlovsk-Kamchatsky

The paper presents the combined use of botulinum toxin type A and the antidepressant venlafaxine in patients with chronic migraine. The findings indicate the efficacy and safety of the proposed therapeutic strategy that has simultaneously an impact on different pathophysiological mechanisms of migraine as a primary disease and on comorbidities and modifiable factors for chronicity of headache, the most important of which are depression and excessive use of analgesics.
Keywords: 
neurology
chronic migraine
comorbidity
depression
quality of life
combined preventive therapy
botulinum toxin type A
venlafaxine

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Ayzenberg I., Katsarava Z., Sborowski A. et al. The prevalence of primary headache disorder in Russia: a countrywide survey // Cephalalgia. – 2012; 32 (5): 373–81.
  2. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version) // Cephalalgia. – 2013; 33 (9): 629–808.
  3. Artemenko A.R., Kurenkov A.L., Belomestova K.V. Klassifikatsija, diagnostika i lechenie hronicheskoj migreni: obzor novyh dannyh // Zhurn. nevrol. i psihiat. – 2013; 113 (11): 91–6.
  4. Osipova V.V., Voznesenskaja T.G. Komorbidnost' migreni: obzor literatury i podhody k izucheniju // Zhurn. nevrol. i psihiat. – 2007; 107 (3): 64–71.
  5. Silberstein S. Preventive migraine treatment // Continuum (Minneap Minn). – 2015; 21 (4): 973–89.
  6. Silberstein S., Lipton R., Dodick D. et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures // Headache. – 2009; 49 (8): 1153–62.
  7. Aurora S., Dodick D., Turkel C. et al. Onabotulinum-toxin A for treatment of chronic migraine: Result from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial // Cephalalgia. – 2010; 30: 793–803.
  8. Diener H., Dodick D., Aurora S. et al. Onabotulinum-toxin A for treatment of chronic migraine: Result from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial // Cephalalgia. – 2010; 30: 804–14.
  9. Latysheva N.V., Filatova E.G., Tabeeva G.R. i dr. Prakticheskie voprosy vedenija patsientov s hronicheskoj migren'ju. Rekomendatsii rossijskih ekspertov // Nervno-myshechnye bolezni. – 2015; 3: 31–6.
  10. D’Amico D., Curone M., Tullo V. et al. Polytherapy for the prophylaxis of chronic migraine: an Italian survey // Neurol. Sci. – 2011; 32 (Suppl. 1): 185–8.
  11. Peterlin B., Calhoun A., Sherry S. et al. Rational combination therapy in refractory migraine // Headache. – 2008; 48: 805–19.
  12. Wiendels N., van Haestregt A., Knuistingh Neven A. et al. Chronic frequent headache in the general population: comorbidity and quality of life // Cephalalgia. – 2010; 26 (12): 1443–50.
  13. Buse D., Manack A., Serrano D. et al. Sociodemogaphic and comorbidity profiles of chronic migraine and episodic migraine sufferers // J. Neurol. Neurosurg. Psychiatry. – 2010; 81 (4): 428–32.
  14. Krymchantowski A., Silva M., Barbosa J. et al. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a doubleblind study // Headache. – 2002; 42: 510–4.
  15. Domingues R., Silva A., Domingues S. et al. A double-blind randomized controlled trial of low dose of propranolol, nortrypiline, and the combination of propranolol and nortryptiline for the preventive treatment of migraine // Arq. Neuropsiquiatr. – 2009; 67 (4): 973–7.
  16. Krymchantowski A., Hampshire F. Polytherapy in migraine prevention. Clinical experience with the combination of a tricyclic antidepressant plus a calcium channel blocker // Headache. – 2004; 44: 499–500.
  17. Pascual J., Rivas M., Leira R. Testing the combination betablocker plus topiramate in refractory migraine // Acta Neurol. Scand. – 2007; 115: 81–3.
  18. Aoki K. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A // Neurotoxicology. – 2005; 26: 785–93.
  19. Tatarinova K.V., Artemenko A.R. Vlijanie klinicheskih projavlenij migreni, depressii i narushenija sna na kachestvo zhizni patsientov s hronicheskoj migren'ju // Nervno-myshechnye bolezni. – 2017; 7 (1): 43–53.
  20. Latysheva N.V., Filatova E.G. Effektivnost' venlafaksina pri hronicheskoj ezhednevnoj golovnoj boli // Lechaschij vrach. – 2008; 5: 1–5.
  21. Bulut S., Berilgen M., Baran A. et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: Randomized, double-blind, crossover study // Clin. Neurol. Neurosurg. – 2004; 107: 44–8.
  22. Ozyalcin S., Talu G., Kiziltan E. et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine // Headache. – 2005; 45: 144–52.